Purchase this article with an account.
Rupali K. Naik, Careen Y. Lowder, Sue Lightman, Anne M. Rentz, Jonathan Kowalski, C. Stephen Foster, Rubens Belfort, Jr., Dennis Revicki, Scott M. Whitcup; Normative Comparison of Patient-Reported Outcomes in Patients With Noninfectious Intermediate or Posterior Uveitis. Invest. Ophthalmol. Vis. Sci. 2011;52(14):2729.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To compare vision-related functioning and health-related quality of life (HRQL) of patients with noninfectious intermediate or posterior uveitis to the US general population and normal-vision reference groups.
Secondary analysis of HRQL data administered at baseline to patients with noninfectious intermediate or posterior uveitis, participating in a 26-week, multicenter, masked, randomized, sham-controlled trial of dexamethasone intravitreal implant (n = 224). PRO measures included the NEI VFQ-25, SF-36®, SF-6D, and EQ-5D. SF-36 and SF-6D scores were compared to US general population samples using the National Health Measurement Study (n = 3844) and Medical Expenditure Panel Survey (n = 955) data. EQ-5D scores were compared to the MEPS data. The VFQ-25 data were compared with published VFQ-25 scores from a normal-vision reference group (n = 122).
Uveitis patients had significantly more impaired SF-36 Mental Component Summary scores and SF-6D scores compared to a general US population sample (P < .001). No significant differences were found for the Physical Component Summary scores and EQ-5D scores between the uveitis and general population samples. Based on the VFQ-25, compared with a normal-vision population, the uveitis sample had clinically significant impairments across all VFQ-25 subscales and the composite score, with all subscale score differences exceeding 10 points (P < .001).
Compared to the US general population and normal-vision reference groups, noninfectious intermediate or posterior uveitis results in meaningful reductions in mental health outcomes, HRQL, and vision-related functioning.
Clinical Trial: :
This PDF is available to Subscribers Only